Of the 10 MPO-ANCAINCR patients who experienced a clinical relapse, 7 developed systemic manifestations (with or without concurrent asthma or rhinosinusitis), while 3 exhibited isolated asthma and/or rhinosinusitis without systemic involvement. Here, MPO is linked to asthma.